Cherry Creek Investment Advisors Inc. Makes New $209,000 Investment in Stryker Corporation $SYK

Cherry Creek Investment Advisors Inc. acquired a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 528 shares of the medical technology company’s stock, valued at approximately $209,000.

Other large investors also recently added to or reduced their stakes in the company. Mar Vista Investment Partners LLC increased its stake in Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock worth $33,572,000 after acquiring an additional 8,353 shares during the last quarter. United Services Automobile Association bought a new stake in Stryker during the first quarter worth approximately $2,857,000. AXS Investments LLC increased its stake in Stryker by 13.7% during the first quarter. AXS Investments LLC now owns 8,827 shares of the medical technology company’s stock worth $3,286,000 after acquiring an additional 1,062 shares during the last quarter. Park Edge Advisors LLC bought a new stake in Stryker during the second quarter worth approximately $679,000. Finally, Hendley & Co. Inc. grew its stake in shares of Stryker by 60.3% during the second quarter. Hendley & Co. Inc. now owns 14,018 shares of the medical technology company’s stock valued at $5,546,000 after buying an additional 5,274 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Up 1.3%

Shares of NYSE:SYK opened at $362.74 on Wednesday. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The stock has a market cap of $138.68 billion, a P/E ratio of 48.05, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The business’s 50 day moving average is $376.79 and its 200 day moving average is $381.24. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the prior year, the firm earned $2.87 earnings per share. Stryker’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Sell-side analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Tuesday, September 30th were paid a $0.84 dividend. The ex-dividend date of this dividend was Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker’s dividend payout ratio is 44.15%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of analyst reports. Barclays upped their target price on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Needham & Company LLC upped their target price on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Rothschild & Co Redburn initiated coverage on Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price on the stock. Redburn Partners set a $420.00 target price on Stryker in a research note on Thursday, September 18th. Finally, BTIG Research upped their target price on Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Fourteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $433.37.

Insiders Place Their Bets

In other Stryker news, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is currently owned by corporate insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.